Navigation Links
Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Date:6/6/2008

re and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database.

For more information, please visit the Company's Web site at http://www.synvista.com .

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
2. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
3. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
4. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
5. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
6. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
7. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
10. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
11. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2CMSA Announces New Model ACT Supporting Case Management Programs 55526 1CMSA Announces New Model ACT Supporting Case Management Programs 55526 2CMSA Announces New Model ACT Supporting Case Management Programs 55526 3President Bill Clinton to Speak at Inaugural Chicago House Speaker Series Luncheon 55524 1President Bill Clinton to Speak at Inaugural Chicago House Speaker Series Luncheon 55524 2Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 1Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 2Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 3Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 4Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 5Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 6Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 7Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 8Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 9Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 10Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 11
Breaking Medicine News(10 mins):Health News:Drug shows positive responses, low side-effects in multiple myeloma 2Health News:Minneapolis Dentists, Shamblott Family Dentistry, Ease the Pain and Cost of Emergency Dental Procedures 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 2Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 3Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 4Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 5Health News:Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York 2Health News:Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York 3